Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BICALUTAMIDE Cause Therapy partial responder? 20 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Therapy partial responder have been filed in association with BICALUTAMIDE (Bicalutamide). This represents 0.5% of all adverse event reports for BICALUTAMIDE.

20
Reports of Therapy partial responder with BICALUTAMIDE
0.5%
of all BICALUTAMIDE reports
1
Deaths
2
Hospitalizations

How Dangerous Is Therapy partial responder From BICALUTAMIDE?

Of the 20 reports, 1 (5.0%) resulted in death, 2 (10.0%) required hospitalization.

Is Therapy partial responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BICALUTAMIDE. However, 20 reports have been filed with the FAERS database.

What Other Side Effects Does BICALUTAMIDE Cause?

Malignant neoplasm progression (352) Prostatic specific antigen increased (322) Drug ineffective (268) Fatigue (258) Prostate cancer (258) Asthenia (223) Hot flush (219) Off label use (171) Disease progression (169) Anaemia (164)

What Other Drugs Cause Therapy partial responder?

CYCLOPHOSPHAMIDE (1,397) RITUXIMAB (1,219) DEXAMETHASONE (1,199) PREDNISONE (1,176) PEMBROLIZUMAB (1,125) CARBOPLATIN (1,096) DOXORUBICIN (834) METHOTREXATE (775) VINCRISTINE (707) ETOPOSIDE (670)

Which BICALUTAMIDE Alternatives Have Lower Therapy partial responder Risk?

BICALUTAMIDE vs BICTEGRAVIR BICALUTAMIDE vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS BICALUTAMIDE vs BILASTINE

Related Pages

BICALUTAMIDE Full Profile All Therapy partial responder Reports All Drugs Causing Therapy partial responder BICALUTAMIDE Demographics